Independent Consultants Wanted
Are you an independent consultant? Are you looking for a new platform or channel to help grow and expand your practice? Why not join us! Lacerta Bio is looking…
Menu
Employee-Free Biotechs: A Virtual Panacea?
Last week Reuters published an article summarizing the "virtual" biotech business model. It was a strange article, considering that this is not a new approach. Indeed, we wrote about this…
Made in China: Chidamide
Today, Derek Lowe points out that Shenzhen Chipscreen received CFDA approval for chid amide (Epidaza), the first drug to be completely discovered, developed and approved exclusively in China.…
On Failure
These past few weeks I have noticed how negative and bimodal we have become when clinical results are announced. More and more, Phase II and III results are labeled #FAIL…
Postcards from Trondheim
I was privileged to spend 10+ days traveling to Copenhagen (Denmark), Lund (Sweden), and Trondheim (Norway). During my travels, I met with a number of emerging biotech companies, helped…
LUNCH: A Framework for Business Development
From a consulting perspective, here is how we view business development, using the acronym LUNCH: Learn what the client wants: What is the objective? Is it cash now in the…
The Keys to the Kingdom
There is a terrific article in Nature Biotechnology entitled Keys to the Kingdom. The article discusses a number of issues bioentrepreneurs may encounter when trying to license technology from a…
The Ten Year Venture Fund: A Thing of the Past?
Today's issue of Institutional Investor has an interesting article on the reality of 10-year venture funds. The author presents statistics demonstrating that <10% of ten-year venture funds actually liquidate…
Venture Funding of Therapeutic Innovation: An Important Report
Earlier this week, BIO released what we think is a valuable and important report. Entitled Venture Funding of Therapeutic Innovation, the report analyzes data on venture funding in R&D by…
The Class of 2014: Both Large and Innovative
Lisa Jarvis has prepared a handy overview of the new drug approvals in 2014: For the pharmaceutical industry, 2014 was one for the record books: sky-high merger and acquisition activity, unprecedented…
- Go to the previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 32
- Go to the next page